Graham CA, Chan RW, Chan DY, Chan CP, Wong LK, Rainer TH Matrix metalloproteinase 9 mRNA: an early prognostic marker for patients with acute stroke. Clin Biochem. 2012 Mar;45(4-5):352-5. doi: 10.1016/j.clinbiochem.2011.12.006. Epub 2011 Dec 19.
Lam NY, Rainer TH, Chan LY, Joynt GM, Lo YM Time course of early and late changes in plasma DNA in trauma patients. Clin Chem. 2003 Aug;49(8):1286-91. doi: 10.1373/49.8.1286.
Lam NY, Rainer TH, Wong LK, Lam W, Lo YM Plasma DNA as a prognostic marker for stroke patients with negative neuroimaging within the first 24 h of symptom onset. Resuscitation. 2006 Jan;68(1):71-8. doi: 10.1016/j.resuscitation.2005.05.021. Epub 2005 Dec 1.
Loo JA, Yan W, Ramachandran P, Wong DT Comparative human salivary and plasma proteomes. J Dent Res. 2010 Oct;89(10):1016-23. doi: 10.1177/0022034510380414. Epub 2010 Aug 25.
Puig N, Jimenez-Xarrie E, Camps-Renom P, Benitez S Search for Reliable Circulating Biomarkers to Predict Carotid Plaque Vulnerability. Int J Mol Sci. 2020 Nov 3;21(21):8236. doi: 10.3390/ijms21218236.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.